Methylphenidate in ADHD With Trichotillomania
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00552266|
Recruitment Status : Unknown
Verified October 2007 by Geha Mental Health Center.
Recruitment status was: Recruiting
First Posted : November 1, 2007
Last Update Posted : November 1, 2007
This study will evaluate the safety and effectiveness of methylphenidate in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and trichotillomania.
Trichotillomania is an impulse control disorder. There is growing evidences of the involvement of dopaminergic neurotransmission in the pathophysiology of trichotillomania. Reported increase in the prevalence of ADHD among patients with impulse control disorders, such as pathological gambling as well as trichotillomania, may result from the overlapping pathophisiological background. It is hypothesized that in cases of ADHD comorbid with trichotillomania methtylphenidate treatment will exhibit beneficial effects in both the ADHD and the hair pulling.
|Condition or disease||Intervention/treatment||Phase|
|ADHD Trichotillomania||Drug: Methylphenidate||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania|
|Study Start Date :||October 2007|
|Estimated Study Completion Date :||October 2009|
- Drug: Methylphenidate
tablets 10-60 mg/day administered once or twice daily 6 weeks
- Clinicial administered Massachusetts General Hospital Hair Pulling Scale for trichotillomania [ Time Frame: First 6 weeks of treatment ]
- Clinicial administered ADHD Rating Scale Clinical Global Impressions (CGI) scale for ADHD severity Weekly spontaneous self report of side effects [ Time Frame: Within the first 6 weeks of treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00552266
|Contact: Pavel Golubchik, M.D.||+firstname.lastname@example.org|
|Geha Mental Health Center||Recruiting|
|Petah Tikva, Israel, 49100|
|Principal Investigator:||Pavel Golubchik, M.D.||Geha Mental Health Center|